Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
The meteoric rise of Dupixent has swelled Q2 revenue at Sanofi, pushing up estimates for this year’s sales growth and grabbing analysts’ attention Monday. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
